23 results
SC TO-I
EX-99
SAGE
Sage Therapeutics Inc
23 Jan 24
Issuer tender offer statement
8:13am
with the SEC, (ii) compensatory agreements, arrangements and understandings with our executive officers, as described under the “Executive Compensation” heading
DEFA14A
SAGE
Sage Therapeutics Inc
7 Jun 23
Additional proxy soliciting materials
4:05pm
appropriate weighting to all the changes made to our executive compensation program in response to stockholder feedback in 2022 and early 2023. Following … to our executive compensation program, as summarized below:
We aligned the total compensation for our Chief Executive Officer, including annual
10-K
rninw
6 Mar 15
Annual report
12:00am